Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   
TAT 2018 - Targeted Anticancer Therapies

TAT 2018 - Targeted Anticancer Therapies

05 - 07 Mar

Paris Marriott Rive Gauche Hotel & Conference Centre, Paris, France

Aims

March 2018

Mon Tue Wed Thu Fri Sat Sun
      1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31  

In a constantly evolving oncology environment, ESMO continues to expand its educational offer and conference portfolio and is pleased to announce that as of 2018 ESMO is taking on the TAT Congress, which will now be held on an annual basis in Europe.

The goals and the design of phase 1 studies have changed from just safety/toxicity to now include clinical activity/response and biomarker research.

This new phase 1 paradigm has already led to rapid, conditional, approval of several new cancer therapeutics showing outstanding clinical activity in early-phase studies.

TAT focuses on early-phase development and translational research.

The programme will cover targeted agents, immuno-oncology and combinations involving such agents.

More information is available from the Conference Web Site

Add to Outlook / iCal

There is currently no content available for TAT 2018 - Targeted Anticancer Therapies. Please visit this page again soon.



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation